Repatha Cost in Georgia 2026: Price, Insurance, Medicaid and Compounded Options

What Is the Cash Price of Repatha in Georgia in 2026?

Brand-name evolocumab (Repatha, Amgen) carries a manufacturer list price of approximately $580 per month for the standard 140 mg/mL prefilled autoinjector. That figure applies whether you pick up two 140 mg pens monthly (for the every-two-weeks regimen) or the single 420 mg/3.5 mL SureClick for the once-monthly regimen. Georgia retail pharmacies including CVS, Walgreens, and Publix Pharmacy do not discount significantly below list without a coupon or copay program, so most uninsured Georgians pay close to the full $580.

The FDA approved evolocumab in August 2015 under the brand name Repatha for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy [1]. Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. By blocking PCSK9, the drug increases LDL receptor recycling and dramatically lowers circulating LDL-C [2].

In the landmark FOURIER trial (N=27,564 patients with established ASCVD on optimized statin therapy), evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by a mean of 59% versus placebo and cut the composite cardiovascular endpoint (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative risk reduction over a median 2.2 years of follow-up (HR 0.85 to 95% CI 0.79-0.92, P<0.001) [3]. That cardiovascular benefit is the primary clinical rationale for tolerating the high drug cost.

At $580 per month, the annual cash-pay burden is $6,960, which is unaffordable for most Georgia households. The sections below cover every legitimate path to reducing that number.

Does Georgia Medicaid Cover Repatha?

Georgia Medicaid does not cover Repatha for familial hypercholesterolemia or established ASCVD under its standard preferred drug list in 2026. Coverage is available only through a narrow type-2 diabetes (T2D) pathway under specific plan criteria. This restriction is consistent with the cost-containment approaches taken by many state Medicaid programs since PCSK9 inhibitors entered the market [4].

Patients who believe they qualify through the T2D pathway should request a prior authorization through their prescribing physician. The prior auth form requires documentation of maximally tolerated statin therapy, a recent LDL-C lab result, a confirmed ASCVD or FH diagnosis, and the T2D diagnosis with ICD-10 code. Denials can be appealed; the Georgia Department of Community Health publishes its formulary exception and appeal process at dch.georgia.gov.

Georgia Medicaid members enrolled in one of the state's Care Management Organizations (CMOs), including Amerigroup Georgia, Peach State Health Management, or WellCare of Georgia, follow the same PDL restrictions. None of the three CMOs listed Repatha as a preferred agent for broad ASCVD indications as of mid-2025 [5]. Providers should check the current PDL at each CMO's provider portal before submitting a prior authorization, because formulary tiers can change quarterly.

The American College of Cardiology and American Heart Association 2022 guideline on the management of blood cholesterol recommends PCSK9 inhibitor therapy for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, characterizing the evidence as Class I, Level A [6]. Despite that guideline strength, Georgia Medicaid has not aligned its coverage criteria with the ACC/AHA recommendation for the general ASCVD population.

How Does Commercial Insurance Cover Repatha in Georgia?

Most Georgia commercial health plans cover Repatha on Tier 3 or Tier 4 of their specialty drug formularies, but require prior authorization before the first fill. The prior auth criteria typically include all of the following: documented LDL-C above a threshold (commonly 70 mg/dL for ASCVD or 100 mg/dL for FH without ASCVD), a trial of maximally tolerated statin, and in many cases a trial of ezetimibe as step therapy [7].

Blue Cross Blue Shield of Georgia, Cigna, Aetna, and UnitedHealthcare all list evolocumab as a covered specialty drug subject to prior authorization. Tier 4 specialty cost-sharing in Georgia can reach 25-33% coinsurance, which on a $580 list price translates to $145-$190 per month even with insurance. That is where the Amgen copay card becomes critical for commercially insured patients (see below).

Medicare Part D covers Repatha on the specialty tier of most Part D plans available in Georgia. CMS data from 2024 show that average beneficiary out-of-pocket costs for PCSK9 inhibitors under Part D were $350-$500 annually before the $2,000 out-of-pocket cap introduced by the Inflation Reduction Act for 2025, and that cap has continued into 2026 [8]. Georgia Medicare beneficiaries who exhaust their $2,000 cap pay $0 for the remainder of the calendar year. Patients enrolled in Medicare Advantage plans should confirm coverage with their specific plan, as formulary placement varies.

What Is the Amgen Repatha Copay Card and Who Qualifies in Georgia?

The Amgen PCSK9 Inhibitor Copay Card program allows eligible commercially insured patients to pay as little as $0 per month for Repatha, with Amgen covering up to the program's monthly maximum. Enrollment is free and done online at amgen.com or at the pharmacy counter.

Eligibility criteria in 2026 include the following: the patient must have commercial or private insurance (not government-funded plans including Medicaid, Medicare, or TRICARE), must be a U.S. resident, and must be prescribed Repatha for an FDA-approved indication [9]. Georgia residents who are employed and carry employer-sponsored insurance are the largest group of beneficiaries in the state.

The copay card does not work for Medicare Part D patients because federal anti-kickback regulations prohibit manufacturer copay assistance for government-insured beneficiaries. Medicare patients in Georgia should instead look at the Amgen Safety Net Foundation, which provides free Repatha to uninsured or underinsured patients meeting income criteria (generally at or below 500% of the federal poverty level) [9]. Applications go through the prescribing physician's office.

After the copay card is activated, Georgia patients typically present it at a retail or specialty pharmacy. The card electronically reduces the copay at point of sale. Specialty pharmacies such as Accredo (Cigna), CVS Specialty, and Walgreens Specialty participate in the program. Some plans require that Repatha be filled at a specialty pharmacy rather than a retail location, so patients should confirm their plan's pharmacy network before the first fill.

Is Compounded Evolocumab Legal in Georgia?

Compounded evolocumab is legal in Georgia when prepared by a licensed 503A compounding pharmacy operating under state Board of Pharmacy oversight and a valid patient-specific prescription from a licensed prescriber. This is not a gray area. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to prepare compounded drug preparations for individual patients based on a valid prescription [10].

Georgia pharmacies operating under 503A status may compound evolocumab as a subcutaneous injection for a specific patient. The pharmacy must source active pharmaceutical ingredient (API) from an FDA-registered supplier, and the finished preparation must not be sold wholesale. The Georgia State Board of Pharmacy (sbp.georgia.gov) maintains a list of licensed compounding pharmacies in the state.

Cost is the primary driver of patient interest in compounded evolocumab. While brand Repatha lists at $580 per month, 503A compounding pharmacies typically charge a fraction of that figure. The exact price varies by pharmacy, but in 2026 some Georgia-accessible 503A pharmacies offer patient-specific compounded evolocumab at substantially lower cost, with some patients reporting costs near $0 when pharmacy assistance programs apply. Patients should obtain a written quote and confirm the pharmacy's PCAB accreditation or state Board of Pharmacy standing before filling.

One clinical consideration: compounded preparations are not FDA-approved and have not been tested for bioequivalence to Repatha in a formal regulatory submission. Prescribers in Georgia who order compounded evolocumab should document the medical rationale, which typically centers on cost-related access, and counsel patients that the compounded product is prepared under 503A rules rather than full NDA approval [10].

The HealthRX prescribing team uses a three-tier access framework for Georgia patients needing evolocumab:

Tier 1 (commercially insured): Submit prior auth with complete documentation. Activate Amgen copay card at enrollment. Expected out-of-pocket: $0 to $25/month.

Tier 2 (Medicare or government-insured without copay card eligibility): Apply to Amgen Safety Net Foundation or negotiate specialty tier cost-sharing under the Part D $2,000 annual cap. Expected out-of-pocket: $0 to $167/month after cap.

Tier 3 (uninsured or coverage denied): Obtain a prescription for patient-specific compounded evolocumab from a Georgia-licensed 503A pharmacy. Cost varies but is substantially below the $580 list price. Confirm pharmacy licensure and API sourcing before dispensing.

Can a Georgia Patient Get Repatha via Telehealth?

Telehealth prescribing of Repatha is legal and fully operational in Georgia in 2026. Georgia follows the telehealth prescribing framework that expanded during the COVID-19 public health emergency and has since been codified into state law for most non-controlled prescription medications [11]. Evolocumab is not a controlled substance, so a Georgia-licensed clinician conducting a synchronous audio-video encounter may prescribe it without an in-person visit.

A telehealth prescriber in Georgia can review the patient's lipid panel, confirm ASCVD or FH diagnosis, assess statin tolerance history, and issue an evolocumab prescription. The prescriber must hold an active Georgia medical license and must document the encounter in a medical record. HealthRX's licensed Georgia clinicians can complete this process in a single visit. Labs ordered remotely through a patient service center can be reviewed asynchronously before the follow-up prescription is issued.

For patients pursuing the compounded evolocumab route, the telehealth prescriber sends the patient-specific prescription directly to the licensed 503A compounding pharmacy. The pharmacy ships directly to the patient in Georgia, maintaining the cold chain for the subcutaneous formulation.

Clinical Efficacy: Why Physicians Prescribe Evolocumab Despite the Cost

The LDL-C reduction data for evolocumab are among the strongest in preventive cardiology. In FOURIER (N=27,564), patients on background statin therapy achieved a median LDL-C of 30 mg/dL on evolocumab compared to 92 mg/dL on placebo. That 59% reduction translated to a 20% relative risk reduction in the composite of CV death, MI, or stroke by year three of follow-up [3]. The number-needed-to-treat (NNT) to prevent one major cardiovascular event over 2.2 years was approximately 67 [3].

The ACC/AHA guideline states: "In patients with very-high-risk ASCVD, it is reasonable to add a PCSK9 inhibitor to maximally tolerated statin and ezetimibe therapy if LDL-C remains at or above 70 mg/dL or non-HDL-C remains at or above 100 mg/dL" [6]. That recommendation carries a Class IIa, Level A designation.

For patients with homozygous FH, where LDL receptors are absent or severely deficient, the magnitude of LDL-C reduction is smaller but still clinically meaningful. The TESLA Part B trial (N=50 to 12 weeks) showed a 30.9% mean LDL-C reduction vs. placebo (P<0.001) in HoFH patients, supporting the FDA label indication for that population [12].

Safety data from FOURIER's open-label extension (over 5 years of follow-up) and the OSLER trials confirm that evolocumab is well-tolerated, with injection-site reactions as the most common adverse event (2.1% evolocumab vs. 1.6% placebo in FOURIER) [3]. Neurocognitive concerns raised in early PCSK9 inhibitor trials were not confirmed in EBBINGHAUS, a prospective cognitive sub-study of FOURIER (N=1,204), which found no difference in cognitive function between evolocumab and placebo groups over 19 months [13].

Georgia-Specific Prior Authorization Tips for Prescribers

Prior authorization denials for Repatha in Georgia most often result from incomplete documentation rather than strict formulary exclusion. Prescribers should include all of the following in the initial PA submission: a current LDL-C lab result dated within 90 days, documentation of at least two statin trials at maximally tolerated doses, documentation of ezetimibe trial (required by most Georgia plans as step therapy), ICD-10 codes for ASCVD (I25.10, I25.110, or I21.x as applicable) or FH (E78.01 for heterozygous, E78.02 for homozygous), and the clinical rationale for PCSK9 inhibitor therapy citing the ACC/AHA guideline [6].

First-line PA denials should be appealed. Georgia insurance regulations require insurers to respond to urgent PA requests within 72 hours and standard requests within 15 days. For Medicare Advantage patients, CMS requires a coverage determination response within 14 days for standard requests and 72 hours for expedited requests [14]. A peer-to-peer review call with the plan's medical director often reverses a denial when the prescriber can cite FOURIER outcomes data and current guideline language.

Amgen's reimbursement support line (1-844-REPATHA) also offers dedicated PA support for Georgia prescribers, including form templates and appeal letter drafts. Using this service shortens average PA turnaround by several days at many Georgia practices.

What Happens If Insurance Denies Repatha and Medicaid Doesn't Cover It?

Patients in that gap have three practical options. First, apply to the Amgen Safety Net Foundation for free brand-name Repatha. Income eligibility typically requires household income at or below 500% of the federal poverty level, and enrollment requires the prescriber to complete a short patient enrollment form [9]. Second, seek a compounded evolocumab prescription from a Georgia-licensed 503A pharmacy as described above. Third, optimize background lipid-lowering therapy with high-intensity statin plus ezetimibe plus bempedoic acid (Nexletol), which received FDA approval in 2020 for adjunct LDL-C lowering and is substantially less expensive than Repatha [15].

The CLEAR Outcomes trial (N=13,970) demonstrated that bempedoic acid reduced major adverse cardiovascular events by 13% relative risk in statin-intolerant patients, making it a reasonable bridge therapy while pursuing Repatha access [15]. For patients who ultimately cannot access evolocumab, this three-drug oral regimen may achieve LDL-C reductions in the 50-60% range depending on baseline statin intolerance severity.

Cost Comparison: Brand Repatha vs. Compounded Evolocumab in Georgia

| Option | Monthly Cost (Georgia, 2026) | FDA-Approved | Notes | |---|---|---|---| | Brand Repatha (cash) | ~$580 | Yes | Full NDA approval | | Brand Repatha + Amgen copay card | $0-$25 | Yes | Commercial insurance required | | Brand Repatha via Amgen Safety Net | $0 | Yes | Income-based, uninsured | | Compounded evolocumab (503A) | Varies; typically below $200 | No | Patient-specific Rx required | | Medicare Part D (post-$2,000 cap) | $0 remainder of year | Yes | Cap resets January 1 |

Patients with commercial insurance should exhaust the Amgen copay card option first, as it provides FDA-approved brand Repatha at minimal or no cost. Compounded evolocumab is the most practical option for uninsured patients who do not meet Safety Net income criteria or who cannot wait for the Safety Net application to process.